A Phase 1 interventional study of anacetrapib in Dyslipidemia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-14.
Sponsored by Merck Sharp & Dohme LLC · Phase 1, Interventional, and Treatment
This study will evaluate the Area Under the Curve (AUC(0 to infinity)) of anacetrapib.
325 studies on the registry are indexed under Hepatic Insufficiency; 53 are open to participants now.
This study's enrollment of 24 is below the median of 36 across 220 interventional studies indexed under Hepatic Insufficiency.
Browse Hepatic Insufficiency studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,114 studies on the registry; 133 are open to participants now.
Of its 489 completed or terminated interventional studies of FDA-regulated products, 362 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Moderate Hepatic Patients
Drug: anacetrapib
Healthy Subjects
Drug: anacetrapib
Mild Hepatic Patients
Drug: anacetrapib
Healthy Subjects
Drug: anacetrapib
single dose administration of anacetrapib (MK0859) 100 mg oral tablet
Area Under the Curve (AUC(0 to infinity)) of anacetrapib
Time frame: through 168 hours post dose
Tolerability of a single dose administration of 100mg anacetrapib, measured by the number of clinical and laboratory adverse events
Time frame: through 14 days post dose
No study locations are listed for this record.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Merck Sharp & Dohme LLC